Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes

References

• Sharifi N, Gulley J L, Dahut W L. Androgen deprivation therapy for prostate cancer. Jama 2005; 294: 238–244
   PubMed Web of Science ®Google Scholar
• Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J, Candas B. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005; 26: 361–379
   PubMed Web of Science ®Google Scholar
• Shahinian V B, Kuo Y F, Freeman J L, Goodwin J S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154–164
   PubMed Web of Science ®Google Scholar
• Freedland S J, Terris M K, Platz E A, Presti J C, Jr. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology 2005; 66: 108–113
   PubMed Web of Science ®Google Scholar
• Amling C L. Relationship between obesity and prostate cancer. Curr Opin Urol 2005; 15: 167–171
   PubMed Web of Science ®Google Scholar
• Kane C J, Bassett W, Sadetsky N, Silva S, Wallace K, Pasta D, Cooperberg M, Chan J, Carroll P. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol 2005; 173: 732–736
   PubMed Web of Science ®Google Scholar
• Inaba M, Otani Y, Nishimura K, Takaha N, Okuyama A, Koga M, Azuma J, Kawase I, Kasayama S. Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism 2005; 54: 55–59
   PubMedGoogle Scholar
• Campbell I W. The clinical significance of PPAR gamma agonism. Curr Mol Med 2005; 5: 349–363
   PubMed Web of Science ®Google Scholar
• Rhoden E L, Ribeiro E P, Teloken C, Souto C A. Diabetes mellitus is associated with subnormal serum levels of free testosterone in men. BJU Int 2005; 96: 867–870
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992; 117: 807–811
   PubMed Web of Science ®Google Scholar
• Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994; 17: 405–411
   PubMed Web of Science ®Google Scholar
• Tibblin G, Adlerberth A, Lindstedt G, Bjorntorp P. The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes 1996; 45: 1605–1609
   PubMed Web of Science ®Google Scholar
• Haffner S M, Shaten J, Stern M P, Smith G D, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 143: 889–897
   PubMed Web of Science ®Google Scholar
• Stellato R K, Feldman H A, Hamdy O, Horton E S, McKinlay J B. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23: 490–494
   PubMed Web of Science ®Google Scholar
• Oh J Y, Barrett-Connor E, Wedick N M, Wingard D L. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25: 55–60
   PubMed Web of Science ®Google Scholar
• Svartberg J, Jenssen T, Sundsfjord J, Jorde R. The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. The Tromso Study. Diabetes Metab 2004; 30: 29–34
   PubMed Web of Science ®Google Scholar
• Laaksonen D E, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T P, Valkonen V P, Salonen R, Salonen J T. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036–1041
   PubMed Web of Science ®Google Scholar
• Haffner S M, Karhapaa P, Mykkanen L, Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 1994; 43: 212–219
   PubMed Web of Science ®Google Scholar
• Birkeland K I, Hanssen K F, Torjesen P A, Vaaler S. Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 1993; 76: 275–278
   PubMed Web of Science ®Google Scholar
• Abate N, Haffner S M, Garg A, Peshock R M, Grundy S M. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002; 87: 4522–4527
   PubMed Web of Science ®Google Scholar
• Kaufman J M, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833–876
   PubMed Web of Science ®Google Scholar
• Muller M, Grobbee D E, den Tonkelaar I, Lamberts S W, van der Schouw Y T. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618–2623
   PubMed Web of Science ®Google Scholar
• Morley J E, Kaiser F E, Perry H M, 3rd, Patrick P, Morley P M, Stauber P M, Vellas B, Baumgartner R N, Garry P J. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410–413
   PubMed Web of Science ®Google Scholar
• Harman S M, Metter E J, Tobin J D, Pearson J, Blackman M R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724–731
   PubMed Web of Science ®Google Scholar
• Feldman H A, Longcope C, Derby C A, Johannes C B, Araujo A B, Coviello A D, Bremner W J, McKinlay J B. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87: 589–598
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Hardin M, Dwyer A A, Valassi E, Yialamas M, Elahi D, Hayes F J. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005; 90: 2636–2641
   PubMed Web of Science ®Google Scholar
• Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005; 174: 827–834
   PubMed Web of Science ®Google Scholar
• Kapoor D, Malkin C J, Channer K S, Jones T H. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63: 239–250
   PubMed Web of Science ®Google Scholar
• Blouin K, Després J, Couillard C, Tremblay A, Prud'homme D, Bouchard C, Tchernof A. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 2005; 54: 1034–1040
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Mootha V K, Dwyer A A, Hardin M, Lee H, Eriksson K F, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes F J. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28: 1636–1642
   PubMed Web of Science ®Google Scholar
• Mootha V K, Lindgren C M, Eriksson K F, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267–273
   PubMed Web of Science ®Google Scholar
• Patti M E, Butte A J, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003; 100: 8466–8471
   PubMed Web of Science ®Google Scholar
• Petersen K F, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman D L, DiPietro L, Cline G W, Shulman G I. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140–1142
   PubMed Web of Science ®Google Scholar
• Petersen K F, Dufour S, Befroy D, Garcia R, Shulman G I. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664–671
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Kaufman J M, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male 2002; 5: 98–102
   PubMedGoogle Scholar
• Eri L M, Haug E, Tveter K J. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia. Scand J Clin Lab Invest 1996; 56: 319–325
   PubMed Web of Science ®Google Scholar
• Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne C D, Davis S, Simpson E R, Carani C. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004; 89: 61–70
   PubMed Web of Science ®Google Scholar
• Rochira V, Granata A RM, Madeo B, Zirilli L, Rossi G, Carani C. Estrogens in males: what have we learned in the last 10 years?. Asian J Androl 2005; 7: 3–20
   PubMed Web of Science ®Google Scholar
• Herrmann B L, Janssen O E, Hahn S, Broecker-Preuss M, Mann K. Effects of estrogen replacement therapy on bone and glucose metabolism in a male with congenital aromatase deficiency. Horm Metab Res 2005; 37: 178–183
   PubMedGoogle Scholar
• Dougherty R H, Rohrer J L, Hayden D, Rubin S D, Leder B Z. Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. Clin Endocrinol (Oxf) 2005; 62: 228–235
   PubMed Web of Science ®Google Scholar
• Smith J C, Bennett S, Evans L M, Kynaston H G, Parmar M, Mason M D, Cockcroft J R, Scanlon M F, Davies J S. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261–4267
   PubMed Web of Science ®Google Scholar
• Dockery F, Bulpitt C J, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003; 104: 195–201
   PubMed Web of Science ®Google Scholar
• Shores M M, Matsumoto A M, Sloan K L, Kivlahan D R. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660–1665
   PubMed Web of Science ®Google Scholar
• Keating N L, A. O'Malley J, Smith M R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448–4456
   PubMed Web of Science ®Google Scholar